Paradigm Biopharmaceuticals Ltd PBIGF
$0.14 $0.01 (4.02%) 1D
Last Updated: Aug 21, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
PBIGF Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Paradigm Biopharmaceuticals Ltd is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Paradigm Biopharmaceuticals Ltd. Stock Analysis PBIGF
United States Health Care Micro Cap Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The company is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. The company develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. The company is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
Paradigm Biopharmaceuticals Ltd (PBIGF) Chart
Financial Metrics & Statements of Paradigm Biopharmaceuticals Ltd (PBIGF)
FAQ's for Paradigm Biopharmaceuticals Ltd (PBIGF)
- As of August 2026, Paradigm Biopharmaceuticals Ltd PBIGF is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Paradigm Biopharmaceuticals Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Paradigm Biopharmaceuticals Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Paradigm Biopharmaceuticals Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Paradigm Biopharmaceuticals Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Paradigm Biopharmaceuticals Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Paradigm Biopharmaceuticals Ltd (PBIGF)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
